Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 55, 56126, Pisa, Italy.
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RMN), FMTS, 67000, Strasbourg, France.
Sci Rep. 2019 Jan 29;9(1):891. doi: 10.1038/s41598-018-37385-x.
L-γ-Glutamyl-p-nitroanilide (GPNA) is widely used to inhibit the glutamine (Gln) transporter ASCT2, but recent studies have demonstrated that it is also able to inhibit other sodium-dependent and independent amino acid transporters. Moreover, GPNA is a well known substrate of the enzyme γ-glutamyltransferase (GGT). Our aim was to evaluate the effect of GGT-mediated GPNA catabolism on cell viability and Gln transport. The GGT-catalyzed hydrolysis of GPNA produced cytotoxic effects in lung cancer A549 cells, resulting from the release of metabolite p-nitroaniline (PNA) rather than from the inhibition of Gln uptake. Interestingly, compounds like valproic acid, verapamil and reversan were able to increase the cytotoxicity of GPNA and PNA, suggesting a key role of intracellular detoxification mechanisms. Our data indicate that the mechanism of action of GPNA is more complex than believed, and further confirm the poor specificity of GPNA as an inhibitor of Gln transport. Different factors may modulate the final effects of GPNA, ranging from GGT and ASCT2 expression to intracellular defenses against xenobiotics. Thus, other strategies - such as a genetic suppression of ASCT2 or the identification of new specific inhibitors - should be preferred when inhibition of ASCT2 function is required.
L-γ-谷氨酰对硝基苯胺(GPNA)被广泛用于抑制谷氨酰胺(Gln)转运体 ASCT2,但最近的研究表明,它也能够抑制其他依赖钠的和独立的氨基酸转运体。此外,GPNA 是γ-谷氨酰转移酶(GGT)的已知底物。我们的目的是评估 GGT 介导的 GPNA 分解代谢对细胞活力和 Gln 转运的影响。GGT 催化 GPNA 的水解在肺癌 A549 细胞中产生细胞毒性作用,这是由于代谢物对硝基苯胺(PNA)的释放而不是 Gln 摄取的抑制所致。有趣的是,像丙戊酸、维拉帕米和 reversan 这样的化合物能够增加 GPNA 和 PNA 的细胞毒性,表明细胞内解毒机制的关键作用。我们的数据表明,GPNA 的作用机制比人们想象的要复杂,进一步证实了 GPNA 作为 Gln 转运抑制剂的特异性较差。不同的因素可能会调节 GPNA 的最终效果,范围从 GGT 和 ASCT2 的表达到对细胞内异源物质的防御。因此,当需要抑制 ASCT2 功能时,应优先选择其他策略,例如 ASCT2 的遗传抑制或新的特异性抑制剂的鉴定。